About the Journal

Download [This article belongs to Volume - 62, Issue - 10]

Abstract : To determine whether tamsulosin monotherapy, or combined with flavoxate improves storage symptoms brought on by benign prostatic hyperplasia (BPH). At our teaching hospitals in Iraq, from July 2020 to July 2022, 164 patients older than 50 years with BPH who had persistent storage symptoms despite taking tamsulosin monotherapy were participated in the prospective study. The patients were divided into two groups at random: group A, which contains 82 patients who got flavoxate hydrochloride in addition to their daily dose of tamsulosin, and 82 individuals made up the second group, who additionally received placebo tablets in addition to their once daily tamsulosin dosage. Of the 164 patients who initially participated in the trial, 15 patients were eliminated due to noncompliance and missing follow-up, leaving 75 patients in group A and 74 patients in group B. Patients in groups A and B ranged in age from 52 to 78 and 54 to 77 respectively. The age and other fundamental features of the patients in the two study groups were matched and did not differ statistically (p value > 0.05). After 10 weeks of treatment, there were statistically significant improvement in group A's total IPSS, storage subscore, and quality of life (p value>0.05), with no significant improvement in voiding subscore and Q max. Tamsulosin monotherapy with the addition of flavoxate significantly reduced the persistence of storage symptoms in BPH patients.